ADI PEG20: Clinical Trials

20 trials of ADI PEG20, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 6 terminated, 2 withdrawn, 1 active not recruiting. 20 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 9, Terminated 6, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 26Terminated 2, Completed 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1

Follow ADI PEG20: new trials by email Literature Review of ADI PEG20 trials Research Report on ADI PEG20

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV)
Phase 1 / Phase 2Not yet recruitingSabine Mueller, MD, PhD972027-06-012026-11-09
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts
Phase 1TerminatedWashington University School of Medicine62024-03-142026-09-03
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
ADI-PEG 20, Cabazitaxel, Carboplatin - Prostate Cancer
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center302024-02-292026-09-18
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Atezolizumab, Bevacizumab, ADI-PEG 20 - Metastatic Hepatocellular Carcinoma
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2023-08-082024-08-26
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
ADI-PEG 20, Gemcitabine, Docetaxel - Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
Phase 1 / Phase 2TerminatedWashington University School of Medicine312023-04-052026-07-27
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
ADI-PEG 20 - Acute Myeloid Leukemia, Adult
Phase 1Active not recruitingPolaris Group382022-04-052026-10-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
ADI PEG20, Nivolumab, Ipilimumab - Uveal Melanoma
Phase 1CompletedMemorial Sloan Kettering Cancer Center92019-04-162025-05-15
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
Atezolizumab, Pemetrexed, Carboplatin - Carcinoma, Non-Small-Cell Lung
Phase 1WithdrawnQueen Mary University of London2018-06-012020-02-25
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
ADI PEG20, Pembrolizumab - Advanced Solid Cancers
Phase 1TerminatedPolaris Group332017-07-142022-04-27
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
ADI-PEG 20, Cytarabine - Acute Myeloid Leukemia
Phase 1TerminatedPolaris Group232017-01-202020-03-05
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
ADI-PEG 20 - Advanced Pancreatic Cancer
Phase 1CompletedPolaris Group212014-11-172020-10-01
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
ADI-PEG 20 - Hepatocellular Carcinoma
Phase 1CompletedPolaris Group82014-11-012016-03-04
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
ADI-PEG 20 plus modified FOLFOX6 - Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma
Phase 1 / Phase 2TerminatedPolaris Group1402014-11-012022-04-25
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
ADI-PEG 20 - Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Phase 1TerminatedPolaris Group852014-04-232020-09-25
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
ADI-PEG 20 - HER2 Negative Metastatic Breast Cancer
Phase 1CompletedPolaris Group152014-04-012016-04-14
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
ADI-PEG 20 - Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Phase 1CompletedPolaris Group82012-09-012016-02-25
Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient
ADI-PEG 20 - Argininosuccinate Synthetase Deficient
Phase 1CompletedPolaris Group82011-12-012014-04-09
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
ADI-PEG 20 - Solid Tumors, Prostate Cancer
Phase 1CompletedPolaris Group432011-09-062018-09-13
Study of ADI-PEG 20 in Patients With Advanced Melanoma
ADI PEG 20 - Metastatic Melanoma, Skin Cancer
Phase 1 / Phase 2CompletedLudwig Institute for Cancer Research312007-07-012022-10-25
ADI-PEG in Patients With Metastatic Melanoma
ADI PEG - Melanoma, Neoplasm Metastasis
Phase 1CompletedFDA Office of Orphan Products Development152001-09-012015-03-25

Conditions studied

Carcinoma, Hepatocellular (4)  ·  Melanoma (3)  ·  Uveal Melanoma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Glioma (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Carcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)  ·  Ichthyosis, X-Linked (1)  ·  Neoplasm Metastasis (1)  ·  Ovarian Neoplasms (1)  ·  Sarcoma (1)

Sponsors

Polaris Group (11)  ·  M.D. Anderson Cancer Center (2)  ·  Washington University School of Medicine (2)  ·  FDA Office of Orphan Products Development (1)  ·  Ludwig Institute for Cancer Research (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Queen Mary University of London (1)  ·  Sabine Mueller, MD, PhD (1)

Countries

United States (17)  ·  Taiwan (4)  ·  United Kingdom (2)  ·  China (1)  ·  Italy (1)  ·  South Korea (1)

Top investigators

Siqing Fu, MD (2)  ·  Alexander Shoushtari, MD (1)  ·  Ana Aparicio, MD (1)  ·  Anna Pavlick, DO (1)  ·  Christine Auberle, M.D. (1)  ·  Cynthia Herzog, MD (1)  ·  Gary Schwartz, MD (1)  ·  Ghassan Abou-Alfa, MD (1)  ·  James Harding, MD (1)  ·  Jedd Wolchok, MD, PhD (1)  ·  John S Bomalaski, MD (1)  ·  Maeve Lowery, MD (1)  ·  Mia Weiss, M.D. (1)  ·  Peter Szlosarek (1)  ·  Peter Szlosarek, MD, PhD (1)

Results publications

PMID 22864522, PMID 30796035, PMID 33787078, PMID 34382365, PMID 35466524